Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• MERCURI-2: Dapagliflozin Before Cardiac Surgery Lowers Postoperative AKI Risk
  Starting dapagliflozin one day before elective cardiac surgery reduced the incidence of postoperative acute kidney injury (AKI) during the first seven days after surgery, according to results from the double-blind, placebo-controlled MERCURI-2 trial published July 30 in JAMA.
• FFR in Focus: New Insights on Angiography-Derived Assessment and FFR-NHPR Discordance
  Two studies recently published in JACC: Cardiovascular Interventions provide fresh insights into coronary physiology, suggesting that angiography-derived fractional flow reserve (FFR) may be a practical alternative to wire-based FFR, while highlighting the prognostic significance of definite discordance between FFR and nonhyperemic pressure ratios (NHPR).
• Central Adiposity as Predictor of CV Outcomes | JACC Special Issue on Obesity
  Waist circumference (WC) and waist-to-hip ratio (WHR) provide additional diagnostic and prognostic value compared with conventional BMI categories alone, which may misclassify cardiovascular disease risk, according to results from the Cross-Cohort Collaboration (CCC) Obesity Working Group published Aug. 11 in JACC.
• ACCEL Lite: Evolocumab In Patients Without Significant Atherosclerosis: Results From VESALIUS-CV
  In this interview, Nanette Kass Wenger MD, MACC and Nicholas Marston, MD discuss the VESALIUS-CV Trial.
• ICECAP: Increasing Duration of Therapeutic Hypothermia After OHCA
  Increasing cooling duration in comatose survivors of out-of-hospital cardiac arrest (OHCA) being treated with therapeutic hypothermia did not improve neurological outcomes, according to findings from the multicenter, randomized ICECAP trial published in JAMA.